



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N	A2	(11) International Publication Number: WO 00/34435 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/28451 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 09/206,887 8 December 1998 (08.12.98) US (71) Applicant: CLONTECH LABORATORIES, INC. [US/US]; 1020 East Meadow Drive, Palo Alto, CA 94303 (US). (72) Inventors: LI, Xianqiang; 3989 Aiddlefield Road, Palo Alto, CA 94303 (US). ZHAO, Xiaoning; 110 E. Remington Drive #20, Sunnyvale, CA 94087 (US). JIANG, Xin; 1133 Rejcovich Way, San Jose, CA 95120 (US). FANG, Yu; 43059 Starr Street, Fremont, CA 94539 (US). DUONG, Tommy; 2491 Glen Elm Way, San Jose, CA 95148 (US). KAIN, Steve; 403 Read Avenue, Belmont, CA 94002 (US). (74) Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).		(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: <i>CIS</i> -ELEMENT REPORTER CONSTRUCTS AND USES THEREOF		
(57) Abstract The present invention provides <i>cis</i> element-reporter constructs for measuring transcription. A series of <i>cis</i> elements are linked to a reporter gene to generate <i>cis</i> -acting reporters. Examples of reporter genes are secreted alkaline phosphatase (SEAP), destabilized green fluorescent protein (d2EGFP) and luciferase. Also provided are various applications of such constructs.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CIS-ELEMENT REPORTER CONSTRUCTS AND USES THEREOF

5

BACKGROUND OF THE INVENTIONCross-Reference to Related Applications

10 This application claims benefit of priority of pending non-provisional application U.S. Serial No. 09/206,887, filed December 8, 1998.

Field of the Invention

15 The present invention relates generally to the field of molecular biology of transcription. More specifically, the present invention relates to *cis* element reporter constructs for measuring transcription.

Description of the Related Art

20 Regulation of the activity of transcription factors is believed to be one of the most important biochemical controls to signal transduction, cell proliferation, differentiation, apoptosis, development, and disease. Studying the regulation of an individual transcription factor in various specific biological functional system has yielded a tremendous amount of information; however, the
25 information that one can obtain from the current strategies of studying an individual factor is limited, despite the global functional status of a number of transcription factors. The information is limited because cross-talking among the different signal transduction pathways leads to activation of multiple transcription factors. Therefore, there is a need

to provide a tool to study the interaction and overall effect of various transcription factors.

Green fluorescent protein (GFP) from the jellyfish *Aequorea victoria* is a reporter molecule for monitoring gene expression and protein localization *in vivo*, *in situ* and in real time (1-4). GFP fluoresces bright green upon mere exposure to UV or blue light-unlike other bioluminescent reporters which require additional proteins, substrates, or cofactors to emit light. GFP fluorescence is stable, species independent and can be monitored noninvasively in living cells. GFP fluorescence persists in formaldehyde-fixed cells and is well suited for double-labeling experiments with other fluorescent markers, including the GFP variant enhanced green fluorescent protein (EGFP, GFP_{mut1}; 5-6).

EGFP encodes a protein which has a single, red-shifted excitation peak and fluoresces about 35 times more intensively than wild type GFP when excited at 488 nm (7), due to an increase in its extinction coefficient (Em). To ensure maximal mammalian expression, the coding region of EGFP contains more than 190 silent base mutations which correspond to human codon-usage preferences (7). The red-shifted spectrum and increased expression of EGFP make it ideal for fluorescence microscopy and fluorescence-activated cell sorting (FACS; 5, 8).

Destabilized EGFP (d2EGFP) contains the PEST domain from mouse ornithine decarboxylase (MODC), fused to the C-terminus of EGFP (9). This domain targets EGFP for rapid turnover effectively reducing EGFP's half-life to two hours. The introduction of d2EGFP greatly increases the utility of GFP in studying dynamic cellular-events *in vivo*.

Another reporter molecule, secreted alkaline phosphatase (SEAP, 10-11), is a secreted form of human placental alkaline

phosphatase and has been used as a reporter for the analysis of *cis*-acting DNA sequences and *trans*-acting factors. Secreted alkaline phosphatase is efficiently secreted from cells, and the levels of SEAP activity in the culture medium are directly proportional to changes in intracellular concentrations of SEAP mRNA and protein (10, 12). Secreted alkaline phosphatase differs from native placental alkaline phosphatase (AP) only in the absence of a membrane-anchoring domain. The secreted nature of secreted alkaline phosphatase offers many advantages over other transcription reporter molecules. Most notably, it is not necessary to prepare cell lysates to assay for the reporter protein. Because the transfected cells remain intact, the kinetics of gene expression can be studied easily using the same cultures by sampling the medium repeatedly; therefore, set-up and variability for multiple cultures are essentially eliminated.

Another important advantage of secreted alkaline phosphatase as a transcription reporter is that background signals due to endogenous alkaline phosphatases are nearly absent. Unlike most endogenous alkaline phosphatases, secreted alkaline phosphatase is extremely heat-stable and resistant to the inhibitor L-homoarginine. Therefore, endogenous alkaline phosphatase activity can be eliminated effectively by preheating the culture medium sample as 65°C and assaying in the presence of L-homoarginine.

In addition, luciferase is a widely used reporter. It is one of most sensitive reporters and like GFP and SEAP, may be fused to a transcription factor of interest and used to track the activation of the transcription factor of interest.

The prior art is deficient in the lack of effective means of detecting and measuring the activities of a number of transcription factors. Further, the prior art is deficient in the lack of a construct for

measuring transcription. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

5 The present invention is directed to novel *cis*-acting reporters for measuring transcription. In one embodiment of the present invention, there is provided a *cis* element-reporter construct
10 comprising a *cis* element, a reporter gene and a promoter. Representative *cis* elements include nuclear factor- κ B, heat responsive element, Myc, p53, nuclear factor of activated T cells, activator protein 1 (AP1), serum responsive element, glucocorticoid responsive element and cAMP responsive element. Representative reporter genes include
15 secreted alkaline phosphatase (SEAP), destabilized green fluorescent protein (d2EGFP) and luciferase (Luc). Representative promoters include thymidine kinase promoter and gonadotropin α -gene promoter.

In another embodiment of the present invention, there is
20 provided a method of generating a *cis* element-reporter construct by linking a *cis* element to a promoter and then fusing the element to a reporter gene.

In yet another embodiment of the present invention, there is provided a method of monitoring activation of a transcription factor,
25 comprising the steps of generating a vector comprising a *cis* element, a reporter gene and a promoter, wherein the *cis* element is a component of a DNA sequence to which said transcription factor binds to ensure activity; transfecting a cell line with the vector; and detecting expression of the reporter gene, wherein expression of the reporter

gene indicates activation of the transcription factor. Representative cell lines include CHO, HEK 293, Saos2 and HeLa.

5 In still yet another embodiment of the present invention, there is provided a method of determining whether a gene is involved in a signal transduction pathway, comprising the steps of generating a vector comprising a *cis* element, a reporter gene and a promoter, wherein the *cis* element is a component of a DNA sequence which affects the expression of the a gene; expressing the vector in a cell line, wherein the cell line is associated with the signal transduction pathway;
10 and detecting the expression of the reporter gene, wherein expression of the reporter gene indicates the involvement of the gene in the signal transduction pathway.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of
15 the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

20

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may
25 be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

30

Figure 1 shows the restriction map of pNF- κ B-SEAP.

Figure 2 shows the restriction map of pNF- κ B-d2EGFP.

Figure 3 shows the restriction map of pNF- κ B-Luc.

Figure 4 shows mediated induction of transcription factors in HEK 293 cells. Twenty four hours after transfection, cells were
5 treated with an inducer for 6 hours. Samples were collected and measured for SEAP activity. Figure 4A shows TNF-mediated transcriptional induction. Cells were treated with 100 ng/ml TNF; NF κ B and NFAT signaling pathways exhibit 4-fold and 10-fold induction, respectively, when activated by TNF. Figure 4B shows serum-mediated
10 induction of transcription factors in HEK 293 cells. Cells were fed with 10% serum. Multiple pathways were induced, when activated by serum. In both experiments, pTK-SEAP was used as the negative control. (RLU = relative light units)

15

DETAILED DESCRIPTION OF THE INVENTION

The following terms have the definitions set below.

As used herein, "*cis*-element" means a genetic element
20 having the ability to affect the activity of a gene on the same DNA molecule as that genetic element.

As used herein, "reporter" means a molecule (usually a protein) that is expressed in response to or as a result of a particular biological or molecular event.

25 As used herein, "cis-acting reporter" means a protein that is expressed in a measurable manner in response to a molecular event that takes place on the same DNA strand that the DNA which codes for the protein is located.

As used herein, "transcription factor" means any factor that controls genetic transcription.

As used herein, "signal transduction pathway" means the pathway or sequence of molecular events which converts an
5 extracellular signal into cellular activity.

The present invention is directed to a series of *cis* element-reporter constructs and uses thereof.

In one embodiment of the present invention, there is provided a *cis* element-reporter construct comprising a *cis* element, a
10 reporter gene and a promoter. Representative *cis* elements include nuclear factor- κ B, heat responsive element, Myc, p53, nuclear factor of activated T cells, activator protein 1, serum responsive element, glucocorticoid responsive element and cAMP responsive element. In one preferred embodiment, the nuclear factor- κ B has the sequence
15 shown in SEQ ID No: 1. In one preferred embodiment, the heat responsive element has the sequence shown in SEQ ID No: 2. In one preferred embodiment, the Myc has the sequence shown in SEQ ID No: 3. In one preferred embodiment, the p53 has the sequence shown in SEQ ID No: 4. In one preferred embodiment, the nuclear factor of
20 activated T cells has the sequence shown in SEQ ID No: 5. In one preferred embodiment, the activator protein 1 has the sequence shown in SEQ ID No: 6. In one preferred embodiment, the serum responsive element has the sequence shown in SEQ ID No: 7. In one preferred embodiment, the glucocorticoid responsive element has the sequence
25 shown in SEQ ID No: 8. In one preferred embodiment, the cAMP responsive element has the sequence shown in SEQ ID No: 9 or SEQ ID No: 10. Representative reporter genes include secreted alkaline phosphatase (SEAP), destabilized green fluorescent protein (d2EGFP) and luciferase (Luc). Representative promoters include thymidine

kinase promoter, gonadotropin α -gene promoter, and other known by those having ordinary skill in this art.

In another embodiment of the present invention, there is provided a method of generating a *cis* element-reporter construct by linking a *cis* element to a promoter and then fusing the element to a reporter gene.

In yet another embodiment of the present invention, there is provided a method of monitoring activation of a transcription factor, comprising the steps of generating a vector comprising a *cis* element, a reporter gene and a promoter, wherein the *cis* element is a component of a DNA sequence to which said transcription factor binds to ensure activity; transfecting a cell line with the vector; and detecting expression of the reporter gene, wherein expression of the reporter gene indicates activation of the transcription factor. Representative cell lines include CHO, HEK 293, Saos2 and HeLa.

In still yet another embodiment of the present invention, there is provided a method of determining whether a gene is involved in a signal transduction pathway, comprising the steps of generating a vector comprising a *cis* element, a reporter gene and a promoter, wherein the *cis* element is a component of a DNA sequence which affects the expression of a test gene; expressing the vector in a cell line, wherein the cell line is associated with the signal transduction pathway; and detecting the expression of the reporter gene, wherein expression of the reporter gene indicates the involvement of the gene in the signal transduction pathway.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1**Cis-Element**

The following *cis* elements were utilized for constructing
5 cis-acting reporters:

NF- κ B (nuclear factor- κ B) having the sequence of GGGAA
TTTCCGGGAATTTCGGGAATTTCGGGAATTTC (SEQ ID No: 1);

HRE (heat responsive element) having the sequence of
TAGAATGTTCTAGATCTAGAACATTCTAGCTAGAATGTTCTAG (SEQ ID No:
10 2);

Myc having the sequence of CACGTGCACGTGCACGTGCACG
TGCACGTGCACGTG (SEQ ID No: 3);

p53 having the sequence of TCGAGCTTGCCTGGACTTGCCTG
GGCCAGATCTGTCGACGGAGGTCGAGCTTGCCTGGACTTGCCTGCCCACATCT
15 GTCGACGGAGGTCGAGCTTGCCTGGACTTGCCTGCCCACATCTGTCGACGGAG
GTCGAGCCTTGCCTGGACTTGCCTGCCA (SEQ ID No: 4);

NFAT (nuclear factor of activated T cells) having the
sequence of GGAGGAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAA
CTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGT
20 (SEQ ID No: 5);

AP1 (activator protein 1) is an active protein and its activity
is composed primarily by Jun/Fos heterodimers as well as Jun
homodimers. The activity of AP1 responds to growth factors, such as
phorbol ester (TPA), protein kinase C. Ap1 having the sequence of
25 TGAGTCAGTGAGTCACTGACTCACTGACTCATGAGTCAGCTG
ACTC (SEQ ID No: 6);

SRE (serum responsive element) having the sequence of
GATGTCCATATTAGGACATCGATGTCCGAATATGGACATCGATGTCCATATT
AGGACATC (SEQ ID No: 7);

GRE (glucocorticoid responsive element) having the sequence of GGTACATTTTGTCTAGAACAAAATGTACCGGTACATTTTGT TCT (SEQ ID No: 8);

CRE stands for cAMP responsive element. Two CRE elements
5 were utilized: CRE3 (GCACCAGACAGTGACGTCAGCTGCCAGAT
CCCATGGCCGTCATACTGTGACGTCTTTCAGACACCCCATTGACGTCAATGGG
AGAAC: SEQ ID No: 9) and CRE5 (TCGAGCCCATGGCCGTCATACTGTGACG
TCCCCATGGCCGTCATACTGTGACGTCCCCATGGCCGTCATACTGTGACGTCC
CCATGGTCGTCATACTGTGACGTCCCCATGGCCGTCATACTGTGACGTC: SEQ
10 ID No:10).

EXAMPLE 2

Cis-Element/SEAP Constructs

15 A number of *cis* elements were linked to a secreted alkaline phosphatase reporter wherein the secreted alkaline phosphatase was used as a reporter. One advantage of using SEAP as a reporter is that SEAP is secreted into the medium and the medium itself can be collected for the assay without disrupting the cells.

20 In a AP1-SEAP construct, the *cis* element in the construct contains six copies of AP1 binding sequence. In a SRE-SEAP construct, the construct contains three copies of SRE element. In a CRE-SEAP construct, the construct contains three different cAMP responsive elements, responding to cAMP, protein kinase A, forskolin etc. In a
25 GRE-SEAP construct, the construct contains three copies of glucocorticoid responsive element and responds to the glucocorticoid-activated glucocorticoid receptor. In a HRE-SEAP construct, the construct contains three copies of heat responsive element. It responds to a number of types of physiological stress, such as heat. In
30 an NF- κ B-SEAP construct, the construct contains four copies of the NF-

κB binding sequence and responds to a number of stimuli, including TNF. In a NFAT-SEAP construct, the construct contains three copies of NFAT binding sequence and responds to PMA, ionomycin, PKC, etc. In a Myc-SEAP construct, the construct contains six copies of myc binding sequence and responds to myc activation. In a P53-SEAP construct, the construct contains two copies of p53 binding sequence, reporting p53 activation.

EXAMPLE 3

pNF-κB-SEAP Construct

pNF-κB-SEAP (SEQ ID No:11) is especially designed for monitoring the activation of NF-κB signal transduction pathway (13-16). The restriction map of pNF-κB-SEAP is shown in Figure 1. Induction of the pathway enables endogenous NF-κB to bind to the kappa (κ) enhancer element (KB₄) located in the promoter region of the vector, thus activating transcription of the reporter gene.

pNF-κB-SEAP allows expression of the secreted alkaline phosphatase reporter gene (17-19). The secreted alkaline phosphatase reporter coding sequence is followed by the SV40 late polyadenylation signal to ensure proper, efficient processing of the secreted alkaline phosphatase reporter transcript in eukaryotic cells. A synthetic transcription blocker (TB), composed of adjacent polyadenylation and transcription pause sites located upstream of the κ-enhancer, reduces background transcription (20). The vector backbone also contains an f1 origin for single-stranded DNA production, a pUC origin of replication, and an ampicillin resistance gene for propagation and selection in *E.coli*. The SEAP vectors incorporate a number of additional features that improve the sensitivity of secreted alkaline

phosphatase reporter by increasing the efficiency of secreted alkaline phosphatase reporter expression or that enhance the utility of the vectors. These include: the removal of the SV40 small-t intron, which can cause cryptic splicing and reduced expression in some genes and/or cell types (21-22); switching from the early to late polyadenylation signal of SV40, which typically causes a five-fold increase in mRNA levels (23); compact plasmid size; and removal of extraneous sequence from the 3' untranslated region of the SEAP mRNA.

10

EXAMPLE 4

Cis-Element/EGFP Construct

EGFP was also used as a reporter to analyze transcription factors. Destabilized EGFP (d2EGFP) is an autofluorescence protein wherein fluorescence emission of this protein does not require any additional substrates or cofactors. d2EGFP is an ideal reporter to be used in cell-based assays for high throughput drug screening as it allows real-time monitoring of activation of transcription factors. The detection can be made in multiple points.

A set of d2EGFP reporters with different cis-elements were generated, which are used for monitoring different transcription factors. Establishment of stable cell lines that express individual reporters expands application of this cis-element reporter in the cell-based high throughput drug screening.

An NF- κ B-d2EGFP construct also is used to monitor the activation of NF- κ B. This construct responds to a number of stimuli, including TNF and IL1. The AP1-d2EGFP construct is used to monitor the activation of AP1, which responds to growth factors. Additionally, an SRE-d2EGFP construct is used to monitor the activation of Elk1. This

30

construct responds to serum. The GRE-d2EGFP construct was used to monitor the activation of glucocorticoid receptors and responds to glucocorticoid activation. The CRE-d2EGFP construct was used to monitor CREB activation and responds to cAMP and cAMP-mediated protein kinase A (PKA). An NFAT-d2EGFP construct was used to monitor Ca^{++} -mediated NFAT activation which responds to Ca^{++} . The HSE-d2EGFP construct is used to monitor HSF activation and responds to a stress, such as heat. The P53-d2EGFP construct is used to monitor p53 activation, responding to DNA damage. The Myc-d2EGFP construct is used to monitor Myc activation, which responds to cell growth.

To construct the cis-acting d2EGFP reporters, the binding sequences of *cis* element was fused to the thymidine kinase (TK) promoter and d2EGFP gene. Resulting constructs are able to monitor the activation of a number of transcription factors. In CRE-d2EGFP transfected CHO cells, forskolin treatment elevates intracellular cAMP resulting in induction of d2EGFP. In NFAT-d2EGFP transfected HEK 293 cells, ionomycin and PMA treatment activates NFAT resulting in induction of d2EGFP. In GRE-d2EGFP transfected Saos2 cells, dexamethasone treatment activates glucocorticoid receptor (GR) resulting induction of d2EGFP.

EXAMPLE 5

pNF- κ B-d2EGFP Construct

By linking NF- κ B binding sequences and the thymidine kinase promoter, d2EGFP gene was able to detect TNF-mediated activation of NF- κ B. pNF- κ B-d2EGFP (SEQ ID No:12) was designed to monitor the activation of the NF- κ B signal transduction pathway (13-16). The restriction map of pNF- κ B-d2EGFP is shown in Figure 2.

Induction of the pathway enables endogenous NF- κ B to bind to the kappa (κ) enhancer element (KB₄) located in the promoter region of the vector, thus activating transcription of the reporter gene.

d2EGFP is a destabilized variant of the enhanced green fluorescent protein. Unlike the original EGFP protein which is extremely stable, d2EGFP has a half-life of approximately two hours *in vivo* (24). Therefore, d2EGFP provides a more accurate measurement of transient activation by NF- κ B than unmodified EGFP and is ideal for kinetic studies of gene activation. To construct d2EGFP, residues 422-461 of mouse ornithine decarboxylase (MODC) were fused to the C-terminus of EGFP. This region of the mouse ornithine decarboxylase contains a PEST amino acid sequence that targets the protein for degradation results in rapid protein turnover. pNF- κ B-d2EGFP allows for real-time analysis of pNF- κ B activation by either fluorescence microscopy or flow cytometry.

The d2EGFP coding sequence is followed by the SV40 late polyadenylation signal to ensure proper, efficient processing of the d2EGFP transcript in eukaryotic cells. A synthetic transcription blocker (TB), composed of adjacent polyadenylation and transcription pause sites located upstream of the κ enhancer reduces background transcription (20). The vector backbone also contains fl origin for single-stranded DNA production, a pUC origin of replication, and an ampicillin resistance gene for propagation and selection in *E.coli*. The d2EGFP vectors incorporate a number of features that improve the sensitivity of d2EGFP by increasing the efficiency of d2EGFP expression or that enhance the utility of the vectors. These include: the removal of the SV40 small-t intron, which can cause cryptic splicing and reduced expression in some genes and/or cell types (21-22); switching from the early to late polyadenylation signal of SV40, which typically

causes a five-fold increase in mRNA levels (23); compact plasmid size; and removal of extraneous sequence from the 3' untranslated region of the d2EGFP mRNA.

5

EXAMPLE 6

CRE5-d2EGFP Construct

pCRE5-d2EGFP (SEQ ID No:13) was constructed using the pTK-SEAP as the backbone. The thymidine kinase promoter was substituted by 5 copies of CREs (cAMP response elements) fused with gonadotropin α -gene promoter (also called Thyroid-stimulating hormone TSH α subunit). The d2EGFP reporter gene was used instead of secreted alkaline phosphatase. This construct was designed to monitor the cAMP level changes *in vivo*. cAMP elevation within cells upon stimulation should result in the phosphorylation of CREB, which consequently induces the transcription and translation of the reporter gene d2EGFP. The destabilized form of EGFP eliminated the accumulation of EGFP in cells and better represented the changes of its expression level upon stimulation.

20

The stable cell line was generated by stably transfected pCRE5-d2EGFP together with pSV2-neo into CHO-K1 cells. Transfected cells were selected under G418 at a 500 μ g/ml concentration and individual clones were isolated and analyzed for forskolin induction. Three cell clones were selected which show a time course as well as the positive response to forskolin. Clone CRE5-dE #3 has the highest fluorescence intensity and is the easiest to detect induction, since it had five fold increase of fluorescence after induction. Clone CRE5-dE #38 has the highest fold of induction (10 fold) and the lowest background EGFP expression. However, after induction, Clone CRE5-dE

25

#38 had a lower fluorescent intensity than that of clone #3. Clone #38-2 is an intermediate of above two clones, having an 8 fold fluorescence induction and, after induction, the fluorescence intensity was at the similar level of clone #3. These cell clones can be used in cell based high-throughput screening in search of factors involved in cAMP signal transduction pathway.

EXAMPLE 7

10 **Cis-Element/Luciferase Construct**

Luciferase was also used as a reporter to analyze transcription factors. Luciferase is one of most sensitive reporters and is widely used in the art. Due to its sensitivity and popularity, luciferase was selected to link to a *cis* element to form a *cis*-element/luciferase construct for monitoring the activation of transcription factors.

pNF- κ B-Luciferase (pNF- κ B-Luc, SEQ ID No:14) contains a firefly luciferase gene and is designed for monitoring the activation of the NF- κ B signal transduction pathway (13-16). The restriction map of pNF- κ B-Luc is shown in Figure 3. Induction of the pathway enables endogenous NF- κ B to bind to the kappa (κ) enhancer element (KB₄) located in the promoter region of the vector, thus activating transcription of the reporter gene. The luciferase coding sequence is followed by the SV40 late polyadenylation signal to ensure proper, efficient processing of the luciferase transcript in eukaryotic cells. A synthetic transcription blocker, composed of adjacent polyadenylation and transcription pause sites located upstream of the κ -enhancer, reduces background transcription (20). The vector backbone also contains an f1 origin for single-stranded DNA production, a pUC origin

of replication, and an ampicillin resistance gene for propagation and selection in *E.coli*.

The pNF- κ B vectors incorporate a number of features that improve the sensitivity of luciferase by increasing the efficiency of luciferase expression or that enhance the utility of the vectors. These include: the removal of the SV40 small-t intron, which can cause cryptic splicing and reduced expression in some genes and/or cell types (21-22); switching from the early to late polyadenylation signal of SV40, which typically causes a five-fold increase in mRNA levels (23); compact plasmid size; and removal of extraneous sequence from the 3' untranslated region of the luciferase mRNA.

EXAMPLE 8

15 Application of Cis-Acting Reporters in Assaying the Activity of Transcription Factors in Signal Pathways

The activity assay of the present invention may be carried out in a 12 or 24 well plate. This assay can be applied to a lot of studies, such as examining whether a new target gene links to any signal pathways. The assay can be used for establishing a functional status profile of transcription factors for evaluating any biological difference *in vivo*, such as normal cells *versus* differentiated, apoptotic, and cancer cells. The assays of the present invention can also be used to examine and quickly identify biological markers for human diseases. Drug validation is another application of the present assay.

Figure 4 demonstrates mediated induction of transcription factors in HEK 293 cells. Figure 4A shows tumor necrosis factor (TNF)-mediated transcriptional induction. Human embryonic kidney (HEK 293) cells were transfected individually with each reporter vector and

incubated for 24 hr in serum-free media. After incubation with TNF for 6 hr, samples were collected and measured for SEAP activity. The transcriptional profile reveals that, as expected, TNF activated the NF κ B and the NFAT signaling pathways, which are known to play pivotal roles in the transcription of genes involved in the immune response (1-4). Other transcription factors and controls were unaffected by TNF stimulation.

Figure 4B shows serum-mediated induction of transcription factors HEK293 cells. After transfection, cells were cultured in serum-free media for 24 hr and incubated with 10% serum for 6 hr. Samples were collected and measured for SEAP activity as described above. Unlike the TNF-mediated activation of specific pathways (Figure 4A), serum activates multiple transcription factors that induce a variety of signaling events after stimulation.

The following references were cited herein.

1. Chalfie, et al., (1994) Science 263: 802-805.
2. Prasher, et al., (1992) Gene 111: 229-233.
3. Inouye, et al., (1994) FEBS Letters 341: 277-280.
4. Wang, et al., (1994) Nature 369: 400-403.
5. Yang, et al., (1996) Nucleic Acid Res. 24(22): 4592-4593.
6. Cormack, et al., (1996) Gene 173: 33-38.
7. Hass, et al., (1996) Curr. Biol. 6: 315-324.
8. Galbraith, et al., (1995) Methods. Cell Biol. 50: 1-12.
9. Living Colors Destabilized EGFP Vectors (April 1998), CLONTECHniques XIII(2): 16-17.
10. Berger, et al., (1998) Gene 66: 1-10.
11. Kain, et al., (1997) Methods Mol. Biol. 63: 49-60.
12. Cullen, et al., (1992) Methods Enzymol. 216: 362-368.
13. Baeuerle, P.A. & Baltimore, D. (1996) Cell 87:13-20
14. Baeuerle, P.A. (1998) Curr. Biol. 8:R19-R2

15. Peltz, G. (1997) Curr. Opin. Biotechnol. 8:467-473
16. Israel, A. (1997) Nature 388: 519-521
17. Berger, J. et al. (1998) Gene 66:1-10
18. Kain, S.R. (1997) Methods Mol. Biol. 63:49-60
- 5 19. Cullen, B.R. & Malim, M.H. (1992) Methods Enzymol 216:362-368
20. Eggermont, J. & Proudfoot, N. (1993) EMBO J. 12:2539-2548
21. Huang, M.T.F. & Gorman, C.M. (1990) Mol. Cell. Biol. 10:1805-1810
- 10 22. Evans, M.J. & Scarpulla, R.C. (1989) Gene 84:135-142
23. Carswell, S. & Alwine, J.C. (1989) Mol. Cell. Biol. 9:5248-4258

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein
15 incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the
20 present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not
25 intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. A construct for measuring transcription, comprising:
a *cis* element, wherein said *cis* element is selected from the
5 group consisting of nuclear factor- κ B having the sequence shown in
SEQ ID No: 1, heat responsive element having the sequence shown in
SEQ ID No: 2, Myc having the sequence shown in SEQ ID No: 3, p53
having the sequence shown in SEQ ID No: 4, nuclear factor of activated
T cells having the sequence shown in SEQ ID No: 5, alkaline
10 phosphatase 1 having the sequence shown in SEQ ID No: 6, serum
responsive element having the sequence shown in SEQ ID No: 7,
glucocorticoid responsive element having the sequence shown in SEQ
ID No: 8 and cAMP responsive element having the sequence selected
from the group consisting of SEQ ID No: 9 and SEQ ID No: 10;
15 a reporter gene; and
a promoter.

2. The construct of claim 1, wherein said reporter gene
20 is selected from the group consisting of secreted alkaline phosphatase,
destabilized green fluorescent protein and luciferase.

3. The construct of claim 1, wherein said promoter is
25 selected from the group consisting of thymidine kinase promoter and
gonadotropin α -gene promoter.

4. A vector comprising the construct of claim 1.
30

5. The vector of claim 4, wherein said vector is pNF- κ B-SEAP.

5 6. The vector of claim 4, wherein said vector is pNF- κ B-d2EGFP.

7. The vector of claim 4, wherein said vector is pNF- κ B-Luc.
10

8. A method of monitoring activation of a transcription factor, comprising the steps of:

15 generating the construct of claim 1, wherein said *cis*-element is a transcription factor;

transforming a cell line with a vector containing said construct; and

20 detecting the expression of said reporter gene, wherein expression of said reporter gene indicates the activation of said transcription factor.

9. A method of monitoring activation of a transcription factor, comprising the steps of:

25 generating the construct of claim 2;

transforming a cell line with a vector containing said construct; and


detecting the expression of said reporter gene, wherein expression of said reporter gene indicates the activation of said transcription factor.

5

10. The method of claim 9, wherein said cell line is selected from the group consisting of CHO, HEK 293 and Saos2.


10

11. The method of claim 9, wherein said construct is selected from the group consisting of pNF- κ B-SEAP, pNF- κ B-d2EGFP and pNF- κ B-Luc.



TB = Transcription Blocker

FIG. 1



TB = Transcription Blocker

FIG. 2




FIG. 3




FIG. 4A




FIG. 4B

SEQUENCE LISTING

<110> Li, Xianqiang
Zhao, Xiaoning
Fang, Yu
Jiang, Xin
Duong, Tommy
Kain, Steve R.

<120> Cis-Element Reporter Constructs and Uses Thereof

<130> D6170PCT

<141> 1999-12-01

<150> US 09/206,887

<151> 1998-12-08

<160> 14

<210> 1

<211> 40

<212> DNA

<213> artificial sequence

<220>

<223> NF- κ B element

<400> 1

gggaatttcc gggaatttcc gggaatttcc gggaatttcc 40

<210> 2

<211> 43

<212> DNA

<213> artificial sequence

<220>

<223> heat responsive element (HRE)

<400> 2

tagaatgttc tagatctaga acattctagc tagaatgttc tag 43

<210> 3

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Myc element

<400> 3
 cacgtgcacg tgcacgtgca cgtgcacgtg cacgtg 36

<210> 4
 <211> 157
 <212> DNA
 <213> artificial sequence
 <220>
 <223> p53 cis element
 <400> 4
 tcgagcttgc ctggacttgc ctggggccaga tctgtcgacg gaggtcgagc 50
 ttgcctggac ttgcctgccc acatctgtcg acggaggtcg agcttgcttg 100
 gacttgcttg cccacatctg tcgacggagg tcgagccttg cctggacttg 150
 cctgcca 157

<210> 5
 <211> 90
 <212> DNA
 <213> artificial sequence
 <220>
 <223> nuclear factor of activated T cells (NF-AT)
 <400> 5
 ggaggaaaaa ctgtttcata cagaaggcgt ggaggaaaaa ctgtttcata 50
 cagaaggcgt ggaggaaaaa ctgtttcata cagaaggcgt 90

<210> 6
 <211> 46
 <212> DNA
 <213> artificial sequence
 <220>
 <223> alkaline phosphatase 1 (AP1)
 <400> 6
 tgagtcagtg agtcactgac tcactgactc atgagtcagc tgactc 46

<210> 7
 <211> 60
 <212> DNA

<213> artificial sequence
 <220>
 <223> serum responsive element (SRE)
 <400> 7
 gatgtccata ttaggacatc gatgtccgaa tatggacatc gatgtccata 50
 ttaggacatc 60

<210> 8
 <211> 45
 <212> DNA
 <213> artificial sequence
 <220>
 <223> glucocorticoid responsive element (GRE)
 <400> 8
 ggtacatttt gttctagaac aaaatgtacc ggtacatttt gttct 45

<210> 9
 <211> 87
 <212> DNA
 <213> artificial sequence
 <220>
 <223> cAMP responsive element (CRE3)
 <400> 9
 gcaccagaca gtgacgtcag ctgccagatc ccatggccgt cataactgtga 50
 cgtcttttcag acacccatt gacgtcaatg ggagaac 87

<210> 10
 <211> 130
 <212> DNA
 <213> artificial sequence
 <220>
 <223> cAMP responsive element (CRE5)
 <400> 10
 tcgagcccat ggccgtcata ctgtgacgtc cccatggccg tcataactgtg 50
 acgtcccat ggccgtcata ctgtgacgtc cccatggctc tcataactgtg 100
 acgtcccat ggccgtcata ctgtgacgtc 130

<210> 11
 <211> 4846
 <212> DNA
 <213> artificial sequence
 <220>
 <223> synthesized pNF-KB-SEAP construct
 <400> 11

```

ggtaccgagc tcttacgcgt gctagcggga atttccggga atttccggga 50
atttccggga atttccagat ctgccgcccc gactgcatct gcggtgttcga 100
attcgccaat gacaagacgc tgggcgggggt ttgtgtcatc atagaactaa 150
agacatgcaa atatatttct tccgggggaca ccgccagcaa acgcgagcaa 200
cggggccacgg ggatgaagca gaagcttcga atcgcggaatt cggccaccat 250
gctgctgctg ctgctgctgc tgggcctgag gctacagctc tccctgggca 300
tcatcccagt tgaggaggag aaccgggact tctggaaccg cgaggcagcc 350
gaggccctgg gtgccgcaa gaagctgcag cctgcacaga cagccgcaa 400
gaacctcatc atcttcctgg gcgatgggat gggggtgtct acggtgacag 450
ctgccaggat cctaaaaggg cagaagaagg acaaactggg gcctgagata 500
cccctggcca tggaccgctt cccatatgtg gctctgtcca agacatacaa 550
tgtagacaaa catgtgccag acagtggagc cacagccacg gcctacctgt 600
gcggggtcaa gggcaacttc cagaccattg gcttgagtgc agccgcccgc 650
tttaaccagt gcaacacgac acgcggcaac gaggtcatct ccgtgatgaa 700
tcgggccaag aaagcaggga agtcagtggg agtggttaacc accacacgag 750
tgcagcacgc ctgccagcc ggcacctacg cccacacggt gaaccgcaac 800
tggtactcgg acgcccagct gcctgcctcg gcccgccagg aggggtgcca 850
ggacatcgct acgcagctca tctccaacat ggacattgac gtgatcctag 900
gtggaggccg aaagtacatg tttcgcattg gaaccccaga ccctgagtac 950
ccagatgact acagccaagg tgggaccagg ctggacggga agaattctggt 1000
gcaggaatgg ctggcgaagc gccagggtgc ccggtatgtg tggaaccgca 1050
ctgagctcat gcaggcttcc ctggaccctg ctgtgaccca tctcatgggt 1100
ctctttgagc ctggagacat gaaatacagag atccaccgag actccacact 1150
ggacccctcc ctgatggaga tgacagaggc tgccctgcgc ctgctgagca 1200
ggaacccccg cggcttcttc ctcttcgtgg aggggtggtc catcgaccat 1250
ggtcatcatg aaagcagggc ttaccgggca ctgactgaga cgatcatgtt 1300
cgacgacgcc attgagaggg cggggccagct caccagcgag gaggacacgc 1350
tgagcctcgt cactgccgac cactcccacg tcttctcctt cggaggctac 1400
cccctgcgag ggagctccat cttcgggctg gccctggca aggcccggga 1450
caggaaggcc tacacggtcc tcctatacgg aaacgggtcca ggctatgtgc 1500
tcaaggacgg cggccggccg gatgttacgg agagcgagag cgggagcccc 1550
  
```


gagtatcggc agcagtcagc agtgcccctg gacgaagaga cccacgcagg 1600
 cgaggacgtg gcggtgttcg cgcgcggccc gcaggcgcac ctggttcacg 1650
 gcgtgcagga gcagaccttc atagcgcacg tcatggcctt cgccgcctgc 1700
 ctggagccct acaccgcctg cgacctggcg ccccccgcgg gcaccaccga 1750
 cgccgcgcac ccgggttact ctagagtcgg ggccggccggc cgcttcgagc 1800
 agacatgata agatacattg atgagtttgg acaaaccaca actagaatgc 1850
 agtgaaaaaa atgctttatt tgtgaaattt gtgatgctat tgctttattt 1900
 gtaaccatta taagctgcaa taaacaagtt aacaacaaca attgcattca 1950
 ttttatgttt cagggttcagg gggagggtgtg ggagggtttt taaagcaagt 2000
 aaaacctcta caaatgtggt aaaatcgata aggatccgtc gaccgatgcc 2050
 cttgagagcc ttcaaccagc tcagctcctt ccggtggggc cggggcatga 2100
 ctatcgtcgc cgcacttatg actgtcttct ttatcatgca actcgttaga 2150
 cagggtgccg cagcgtctct ccgcttcctc gctcactgac tcgctgcgct 2200
 cggtcgttcg gctgcggcga gcggtatcag ctactcaaa ggccgtaata 2250
 cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa 2300
 aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcggttt 2350
 tccataggct ccgccccctt gacgagcatc aaaaaaatcg acgctcaagt 2400
 cagaggtggc gaaacccgac aggactataa agataccagg cgtttcccc 2450
 tggaagctcc ctctgcgct ctctgttcc gaccctgccg cttaccggat 2500
 acctgtccgc ctttctccct tcgggaagcg tggcgcttct tcatagctca 2550
 cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg 2600
 tgtgcacgaa cccccgctt agcccgaccg ctgcgcctta tccggtaact 2650
 atcgtcttga gtccaaccg gtaagacacg acttatcgcc actggcagca 2700
 gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 2750
 gttcttgaag tgggtggccta actacggcta cactagaagg acagtatttg 2800
 gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc 2850
 tcttgatccg gcaaaaaaac caccgctggg agcgggtggt tttttgtttg 2900
 caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga 2950
 tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg 3000
 attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa 3050
 ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt 3100
 ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt 3150
 ctatttcgtt catccatagt tgctgactc ccgctcgtgt agataactac 3200
 gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag 3250
 acccacgctc accggctcca gatttatcag caataaacca gccagccgga 3300
 agggccgagc gcagaagtgg tcctgcaact ttatccgct ccatccagtc 3350
 tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt 3400
 tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg 3450

```

tttgggtatgg cttcattcag ctccgggttcc caacgatcaa ggcgagttac 3500
atgatccccc atgttgtgca aaaaagcggg tagctccttc ggtcctccga 3550
tcgttgtcag aagtaagttg gccgcagtgt tatcactcat ggttatggca 3600
gcaactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 3650
gactgggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac 3700
cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc 3750
agaactttta aagtgtctcat cattggaaaa cgttcttcgg ggcgaaaact 3800
ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg 3850
cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga 3900
gcaaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 3950
gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt 4000
atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa 4050
aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga 4100
cgcgccctgt agcggcgcat taagcgcggc ggggtgtggtg gttacgcgca 4150
gcgtgaccgc tacacttgcc agcgccctag cgcccgtcc tttcgctttc 4200
ttcccttctt ttctcgccac gtctcgccggc tttccccgtc aagctctaaa 4250
tcggggggctc cctttagggt tccgatttag tgctttacgg cacctcgacc 4300
ccaaaaaact tgattagggt gatggttcac gtagtgggcc atcgccctga 4350
tagacggttt ttcgcccttt gacgttggag tccacgttct ttaatagtgg 4400
actcttggtc caaactggaa caacactcaa ccctatctcg gtctattctt 4450
ttgatttata agggattttg ccgatttcgg cctattgggt aaaaaatgag 4500
ctgattttaac aaaaatttaa cgcgaaattt aacaaaatat taacgtttac 4550
aatttcccat tcgccattca ggctgcgcaa ctggtgggaa gggcgatcgg 4600
tgcggggctc ttcgctatta cgccagccca agctaccatg ataagtaagt 4650
aatattaagg tacgggaggt acttgagcg gccgcaataa aatatcttta 4700
ttttcattac atctgtgtgt tggttttttg tgtgaatcga tagtactaac 4750
atacgctctc catcaaaaca aaacgaaaca aaacaaacta gcaaaatagg 4800
ctgtccccag tgcaagtgca ggtgccagaa catttctcta tcgata 4846

```

<210> 12

<211> 4163

<212> DNA

<213> artificial sequence

<220>

<223> synthesized pNF-KB-d2EGFP construct

<400> 12

```

ggtaccgagc tcttacgcgt gctagcggga atttccggga atttccggga 50

```

atttccggga	atttccagat	ctgccgcccc	gactgcatct	gcgtgttcga	100
attcgccaat	gacaagacgc	tgggcggggt	ttgtgtcatc	atagaactaa	150
agacatgcaa	atatatttct	tccggggaca	ccgccagcaa	acgcgagcaa	200
cgggccacgg	ggatgaagca	gaagcttccc	cgaattccgg	atgggtgagca	250
agggcgagga	gctgttcacc	gggggtggtgc	ccatcctggt	cgagctggac	300
ggcgacgtaa	acggccacaa	gttcagcgtg	tccggcgagg	gcgagggcga	350
tgccacctac	ggcaagctga	ccctgaagtt	catctgcacc	accggcaagc	400
tgcccggtgc	ctggcccacc	ctcgtgacca	ccctgacctc	cggcgtgcag	450
tgcttcagcc	gctaccccg	ccacatgaag	cagcacgact	tcttcaagtc	500
cgccatgccc	gaaggctacg	tccaggagcg	caccatcttc	ttcaaggacg	550
acggcaacta	caagaccgcg	gccgaggtga	agttcgaggg	cgacaccctg	600
gtgaaccgca	tcgagctgaa	gggcatcgac	ttcaaggagg	acggcaacat	650
cctgggggcac	aagctggagt	acaactacaa	cagccacaac	gtctatatca	700
tggccgacaa	gcagaagaac	ggcatcaagg	tgaacttcaa	gatccgccac	750
aacatcgagg	acggcagcgt	gcagctcgcc	gaccactacc	agcagaacac	800
ccccatcggc	gacggccccg	tgctgctgcc	cgacaaccac	tacctgagca	850
cccagtcggc	cctgagcaaa	gaccccaacg	agaagcgcg	tcacatggtc	900
ctgctggagt	tcgtgaccgc	cgccggggtc	actctcggca	tggacgagct	950
gtacaagaag	cttagccatg	gcttcccgc	ggaggtggag	gagcaggatg	1000
atggcacgct	gcccattgtct	tgtgcccagg	agagcgggat	ggaccgtcac	1050
cctgcagcct	gtgcttctgc	taggatcaat	gtgtagtcta	gagtcggggc	1100
ggccggccgc	ttcgagcaga	catgataaga	tacattgatg	agtttggaca	1150
aaccacaact	agaatgcagt	gaaaaaaatg	ctttatttgt	gaaatttgtg	1200
atgctattgc	tttatttgta	accattataa	gctgcaataa	acaagttaac	1250
aacaacaatt	gcattcattt	tatgtttcag	gttcaggggg	aggtgtggga	1300
ggttttttta	agcaagtaaa	acctctacaa	atgtggtaaa	atcgataagg	1350
atccgtcgac	cgatgccctt	gagagccttc	aaccagtcac	gctccttcgg	1400
gtgggcgcgg	ggcatgacta	tcgtcgccgc	acttatgact	gtcttcttta	1450
tcatgcaact	cgtaggacag	gtgccggcag	cgctcttcgg	cttcctcgct	1500
cactgactcg	ctgcgctcgg	tcgttcgggt	gcggcgagcg	gtatcagctc	1550
actcaaaggc	ggtaatacgg	ttatccacag	aatcagggga	taacgcagga	1600
aagaacatgt	gagcaaaaagg	ccagcaaaaag	gccaggaacc	gtaaaaaggc	1650
cgcgttgctg	gcgtttttcc	ataggctccg	ccccctgac	gagcatcaca	1700
aaaatcgacg	ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	1750
taccaggcgt	ttccccctgg	aagctccctc	gtgcgctctc	ctgttcggac	1800
cctgccgctt	accggatacc	tgtccgcctt	tctcccttcg	ggaagcgtgg	1850
cgctttctca	tagctcacgc	tgtaggtatc	tcagttcggg	gtaggtcggt	1900
cgctccaagc	tgggctgtgt	gcacgaaccc	cccgttcagc	ccgaccgctg	1950

cgccttatcc ggtaactatc gtcttgagtc caacccggtta agacacgact 2000
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggat 2050
gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 2100
tagaaggaca gtattttggtta tctgcgctct gctgaagcca gttaccttcg 2150
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 2200
ggtaggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 2250
tcaagaagat cttttgatct tttctacggg gtctgacgct cagtggaaacg 2300
aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc 2350
acctagatcc ttttaaatta aaaatgaagt tttaaataca tctaaagtat 2400
atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac 2450
ctatctcagc gatctgtcta tttcggtcat ccatagttgc ctgactcccc 2500
gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtg 2550
tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa 2600
taaaccagcc agccggaagg gccgagcgca gaagtgggtcc tgcaacttta 2650
tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 2700
ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg 2750
tggtgtcacg ctcgctggtt ggtatggctt cattcagctc cggttcccaa 2800
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 2850
ctccttcggt cctccgatcg ttgtcagaag taagtggcc gcagtgttat 2900
cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 2950
gtaagatgct tttctgtgac tggtagtagt tcaaccaagt cattctgaga 3000
atagtgtatg cggcgaccga gttgctcttg cccggcggtca atacgggata 3050
ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 3100
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 3150
gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca 3200
ccagcgtttc tgggtgagca aaacaggaa ggcaaaatgc cgcaaaaaag 3250
ggaataaggc cgacacggaa atgttgaata ctcatactct tcctttttca 3300
atattattga agcatttatc agggttattg tctcatgagc ggatacatat 3350
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc 3400
cgaaaagtgc cacctgacgc gccctgtagc ggcgcatata gcgcggcggg 3450
tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc 3500
ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgccggccttt 3550
ccccgtcaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc 3600
tttacggcac ctcgacccca aaaaacttga ttaggggtgat ggttcacgta 3650
gtggggccatc gccctgatag acggtttttc gccctttgac gttggagtcc 3700
acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 3750
tatctcggtc tattcttttg atttataagg gattttgccg atttcggcct 3800
attggttaaa aatgagctg atttaacaaa aatttaacgc gaattttaac 3850

```

aaaatattaa cgtttacaat ttcccattcg ccattcaggc tgcgcaactg 3900
ttgggaaggg cgatcgggtgc gggcctcttc gctattacgc cagcccaagc 3950
taccatgata agtaagtaat attaaggtac gggagggtact tggagcggcc 4000
gcaataaaat atctttatatt tcattacatc tgtgtgttgg ttttttgtgt 4050
gaatcgatag tactaacata cgctctccat caaaacaaaa cgaaacaaaa 4100
caactagca aaataggctg tcccagtg aagtgcagggt gccagaacat 4150
ttctctatcg ata 4163

```

```

<210>      13
<211>      4300
<212>      DNA
<213>      artificial sequence
<220>
<223>      synthesized pCRE5-d2EGFP
<400>      13

```

```

ggtaccgagc tcttacgcgt gctagcggga atttccggga atttccggga 50
atttccggga atttccagat cctcgagccc atggccgtca tactgtgacg 100
tcccacatggc cgtcatactg tgacgtcccc atggccgtca tactgtgacg 150
tcccacatggc cgtcatactg tgacgtcccc atggccgtca tactgtgacg 200
tcccgcgggc gactaccctt caatcattgg atggaatttc ctgttgatcc 250
cagggttag atgcagggtg aaacactctg ctggtataaa agcagggtgag 300
gacttcatta actgcagtta ctgagaactc ataagacgaa gctaaaatcc 350
ctcttcggaa gcttccccga attccggatg gtgagcaagg gcgaggagct 400
gttcaccggg gtggtgcccc tcttggtcga gctggacggc gacgtaaacg 450
gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc 500
aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc ccgtgccctg 550
gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc ttcagccgct 600
accccgacca catgaagcag cactgacttc tcaagtccgc catgcccga 650
ggctacgtcc aggagcgac catcttcttc aaggacgac gcaactacaa 700
gacccgcgcc gaggtgaagt tcgagggcga caccctggtg aaccgcatcg 750
agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag 800
ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca 850
gaagaacggc atcaaggtga acttcaagat ccgccacaac atcgaggacg 900
gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac 950
ggccccgtgc tgctgcccga caaccactac ctgagcacc agtccgccct 1000
gagcaaagac cccaacgaga agcgcgatca catggtcctg ctggagtctg 1050
tgaccgccc cggtatcact ctcggcattg acgagctgta caagaagctt 1100
agccatggct tcccgcggga ggtggaggag caggatgatg gcacgctgcc 1150

```

catgtcttgt	gcccaggaga	gcgggatgga	ccgtcaccct	gcagcctgtg	1200
cttctgctag	gatcaatgtg	tagtctagag	tcggggcggc	cggccgcttc	1250
gagcagacat	gataagatac	attgatgagt	ttggacaaac	cacaactaga	1300
atgcagtga	aaaaatgctt	tatttgtgaa	atttgtgatg	ctattgcttt	1350
atttgttaacc	attataagct	gcaataaaca	agttaacaac	aacaattgca	1400
ttcattttat	gtttcaggtt	cagggggagg	tgtgggaggt	tttttaaagc	1450
aagtaaaacc	tctacaaatg	tggtaaaatc	gataaggatc	cgtcgaccga	1500
tgcccttgag	agccttcaac	ccagtcagct	ccttccggtg	ggcgcggggc	1550
atgactatcg	tcgccgcact	tatgactgtc	ttctttatca	tgcaactcgt	1600
aggacaggtg	ccggcagcgc	tcttccgctt	cctcgetcac	tgactcgctg	1650
cgctcggtcg	ttcgggtgcg	gcgagcggta	tcagctcact	caaaggcggt	1700
aatacggtta	tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	1750
caaaaggcca	gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	1800
tttttccata	ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	1850
aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	caggcgtttc	1900
cccctggaag	ctccctcggtg	cgctctcctg	ttccgaccct	gccgcttacc	1950
ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	2000
ctcacgctgt	aggtatctca	gttcggtgta	ggtcgttcgc	tccaagctgg	2050
gctgtgtgca	cgaaccccc	gttcagccc	accgctgcgc	cttatccggt	2100
aactatcgtc	ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	2150
agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	ggcgggtgcta	2200
cagagtctct	gaagtgggtg	cctaactacg	gtacactag	aaggacagta	2250
tttggatatct	gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	2300
tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggg	ggtttttttg	2350
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	2400
ttgatctttt	ctacgggggtc	tgacgctcag	tggaacgaaa	actcacgtta	2450
agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	2500
taaattaaaa	atgaagtttt	aaatcaatct	aaagtatata	tgagtaaact	2550
tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	2600
ctgtctattt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	2650
ctacgatacg	ggagggctta	ccatctggcc	ccagtgcctg	aatgataccg	2700
cgagacccac	gctcaccggc	tccagattta	tcagcaataa	accagccagc	2750
cgggaagggcc	gagcgcagaa	gtggctcctg	aactttatcc	gcctccatcc	2800
agtctattaa	ttggttgccg	gaagctagag	taagtagttc	gccagttaat	2850
agtttgcgca	acgttggtgc	cattgctaca	ggcatcgtgg	tgtcacgctc	2900
gtcgtttggt	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	2950
ttacatgatc	ccccatgttg	tgcaaaaaag	cggttagctc	cttcggctct	3000
ccgatcggtg	tcagaagtaa	gttggccgca	gtgttatcac	tcatgggttat	3050

```

ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 3100
ctgtgactgg tgagtactca accaagtcac tctgagaata gtgtatgcgg 3150
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 3200
tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa 3250
aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaaccctact 3300
cgtgcacca actgatcttc agcatctttt actttcacca gcgtttctgg 3350
gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataaggcgca 3400
cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc 3450
atztatcagg gttattgtct catgagcgga tacatatattg aatgtattta 3500
gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac 3550
ctgacgcgcc ctgtagcggc gcattaagcg cggcggtgt ggtggttacg 3600
cgcagcgtga ccgctacact tgccagcgcc ctagcgcccg ctcttttcgc 3650
tttcttcctc tcctttctcg ccacgttcgc cggctttccc cgtcaagctc 3700
taaatcgggg gctcccttta gggttccgat ttagtgcttt acggcacctc 3750
gaccccaaaa aacttgatta gggatgatgg tcacgtagtg ggccatcgcc 3800
ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 3850
gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat 3900
tcttttgatt tataagggat ttgccgatt tcggcctatt ggttaaaaaa 3950
tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa atattaacgt 4000
ttacaatttc ccattcgcca ttcaggctgc gcaactgttg ggaaggcgca 4050
tcggtgcggg cctcttcgct attacgccag cccaagctac catgataagt 4100
aagtaatat aaggtacggg aggtacttgg agcggccgca ataaaatata 4150
tttattttca ttacatctgt gtgttggttt tttgtgtgaa tcgatagtac 4200
taacatacgc tctccatcaa aacaaaacga aacaaaacaa actagcaaaa 4250
taggctgtcc ccagtgcaag tgcaggtgcc agaacatttc tctatcgata 4300

```

```

<210>      14
<211>      4987
<212>      DNA
<213>      artificial sequence
<220>
<223>      synthesized pNF-KB-Luc
<400>      14

```

```

ggtaccgagc tcttacgcgt gctagcggga atttccggga atttccggga 50
atttccggga atttccagat ctgccgcccc gactgcatct gcgtgttcga 100
attcgccaat gacaagacgc tgggcggggg ttgtgtcatc atagaactaa 150
agacatgcaa atatatttct tccgggggaca ccgccagcaa acgcgagcaa 200

```

cgggccacgg	ggatgaagca	gaagcttggc	attccggtac	tgttggtaaa	250
gccaccatgg	aagacgcaa	aaacataaag	aaaggcccg	cgccattcta	300
tccgctggaa	gatggaaccg	ctggagagca	actgcataag	gctatgaaga	350
gatacgccct	ggttcctgga	acaattgctt	ttacagatgc	acatatcgag	400
gtggacatca	cttacgctga	gtacttcgaa	atgtccgttc	ggttggcaga	450
agctatgaaa	cgatatgggc	tgaatacaaa	tcacagaatc	gtcgtatgca	500
gtgaaaactc	tcttcaattc	tttatgccgg	tgttgggcgc	gttatatttc	550
ggagttgcag	ttgcgcccgc	gaacgacatt	tataatgaac	gtgaattgct	600
caacagtatg	ggcatttcgc	agcctaccgt	gggtgttcgtt	tccaaaaagg	650
ggttgcaaaa	aattttgaac	gtgcaaaaaa	agctcccaat	catccaaaaa	700
attattatca	tggattctaa	aacggattac	cagggatttc	agtcgatgta	750
cacgttcgtc	acatctcatc	tacctcccgc	ttttaatgaa	tacgattttg	800
tgccagagtc	cttcgatagg	gacaagacaa	ttgcactgat	catgaactcc	850
tctggatcta	ctggtctgcc	taaagggtgc	gctctgcctc	atagaactgc	900
ctgcgtgaga	ttctcgcatt	ccagagatcc	tatttttggc	aatcaaatca	950
ttccggatac	tgcgatttta	agtgttggtc	cattccatca	cggtttttgg	1000
atgtttacta	cactcggata	tttgatatgt	ggatttcgag	tcgtcttaata	1050
gtatagattt	gaagaagagc	tgtttctgag	gagccttcag	gattacaaga	1100
ttcaaagtgc	gctgctggtg	ccaaccctat	tctccttctt	cgccaaaage	1150
actctgattg	acaaatacga	tttatctaat	ttacacgaaa	ttgcttcttg	1200
tggcgctccc	ctctctaagg	aagtcgggga	agcgggtgcc	aagagggtcc	1250
atctgccagg	tatcaggcaa	ggatatgggc	tactgagac	tacatcagct	1300
attctgatta	caccgaggga	ggatgataaa	ccgggcgcgg	tcggtaaagt	1350
tgttccattt	tttgaagcga	aggttgtgga	tctggatacc	gggaaaacgc	1400
tgggcgttaa	tcaaagaggc	gaactgtgtg	tgagagggtcc	tatgattatg	1450
tccggttatg	taaacaatcc	ggaagcgacc	aacgccttga	ttgacaagga	1500
tggatggcta	cattctggag	acatagctta	ctgggacgaa	gacgaacact	1550
tcttcatcgt	tgaccgctg	aagtctctga	ttaagtacaa	aggctatcag	1600
gtggctcccg	ctgaattgga	atccatcttg	ctccaacacc	ccaacatctt	1650
cgacgcaggt	gtcgcaggtc	ttcccagcga	tgacgcgggt	gaacttcccg	1700
ccgccgttgt	tgttttggag	cacggaaaga	cgatgacgga	aaaagagatc	1750
gtggattacg	tcgccagtca	agtaacaacc	gcgaaaaagt	tgcgcgagg	1800
agttgtgttt	gtggacgaag	taccgaaagg	tcttaccgga	aaactcgacg	1850
caagaaaaat	cagagagatc	ctcataaagg	ccaagaagg	cggaaagatc	1900
gccgtgtaat	tctagagtcg	gggcggccgg	ccgcttcgag	cagacatgat	1950
aagatacatt	gatgagtttg	gacaaaccac	aactagaatg	cagtgaaaaa	2000
aatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgttaaccatt	2050
ataagctgca	ataaacaagt	taacaacaac	aattgcattc	attttatgtt	2100

tcagggttcag	ggggaggtgt	gggaggtttt	ttaaagcaag	taaaacctct	2150
acaaatgttg	taaaatcgat	aaggatccgt	cgaccgatgc	ccttgagagc	2200
cttcaaccca	gtcagctcct	tccggtgggc	gcggggcatg	actatcgctc	2250
ccgcacttat	gactgtcttc	tttatcatgc	aactcgtagg	acagggtgcc	2300
gcagcgctct	tccgcttcct	cgctcactga	ctcgctgcgc	tcggtcgttc	2350
ggctgcggcg	agcggtatca	gctcactcaa	aggcggtaat	acggttatcc	2400
acagaatcag	gggataacgc	aggaaagaac	atgtgagcaa	aaggccagca	2450
aaaggccagg	aaccgtaaaa	aggccgcgtt	gctggcgttt	ttccataggc	2500
tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	tcagagggtg	2550
cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	2600
cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	2650
cctttctccc	ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	2700
tatctcagtt	cgggtgtaggt	cgttcgctcc	aagctgggct	gtgtgcacga	2750
accccccggt	cagcccgacc	gctgcgcctt	atccggtaac	tatcgtcttg	2800
agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	agccactggg	2850
aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	2900
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgcg	2950
ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	3000
ggcaaacaaa	ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	3050
gattacgcgc	agaaaaaaag	gatctcaaga	agatcctttg	atcttttcta	3100
cggggtctga	cgctcagtg	aacgaaaact	cacgttaagg	gattttgggtc	3150
atgagattat	caaaaaggat	cttcacctag	atccttttaa	attaaaaatg	3200
aagtttttaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	3250
accaatgctt	aatcagtgag	gcacctatct	cagcgatctg	tctatttctg	3300
tcatccatag	ttgcctgact	ccccgtcgtg	tagataacta	cgatacggga	3350
gggcttacca	tctggcccca	gtgctgcaat	gataccgcga	gaccacgcgt	3400
caccggctcc	agatttatca	gcaataaacc	agccagccgg	aagggccgag	3450
cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	ctattaattg	3500
ttgccgggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcaacg	3550
ttgttgccat	tgctacaggc	atcgtgggtg	cacgctcgtc	gtttggatatg	3600
gcttcattca	gctccgggtc	ccaacgatca	aggcgagtta	catgatcccc	3650
catgttgtgc	aaaaaagcgg	ttagctcctt	cggtcctccg	atcgttgtca	3700
gaagtaagtt	ggccgcagtg	ttatcactca	tggttatggc	agcactgcat	3750
aattctctta	ctgtcatgcc	atccgtaaga	tgcttttctg	tgactgggtga	3800
gtactcaacc	aagtcattct	gagaatagt	tatgcggcga	ccgagttgct	3850
cttgcccggc	gtcaatacgg	gataataacc	cgccacatag	cagaacttta	3900
aaagtgctca	tcattggaaa	acgttcttcg	gggcgaaaac	tctcaaggat	3950
cttaccgctg	ttgagatcca	gttcgatgta	accactcgt	gcacccaact	4000

gatcttcagc atctttttact ttcaccagcg tttctgggtg agcaaaaaca 4050
ggaaggcaaa atgccgcaaa aaaggggaata agggcgacac ggaaatgttg 4100
aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt 4150
attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacia 4200
ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgcgccctg 4250
tagcggcgca ttaagcgcgg cgggtgtggt ggttacgcgc agcgtgaccg 4300
ctacacttgc cagcgcccta gcgcccgcgc ctttcgcttt cttcccttcc 4350
tttctcgcca cgttcgcggg ctttccccgt caagctctaa atcgggggct 4400
cccttttaggg ttccgattta gtgcttttac gcacctcgac ccaaaaaaac 4450
ttgattaggg tgatggttca cgtagtgggc catcgccctg atagacgggt 4500
tttcgccctt tgacgttgga gtccacgttc tttaatagtg gactcttggt 4550
ccaaactgga acaacactca accctatctc ggtctattct tttgatttat 4600
aagggathtt gccgathttgc gcctattggt taaaaaatga gctgatttaa 4650
caaaaattta acgcgaatth taacaaaata ttaacgttta caatttccca 4700
ttcgccattc aggctgcgca actgttggga agggcgatcg gtgcgggcct 4750
cttcgctatt acgccagccc aagctaccat gataagtaag taatattaag 4800
gtacgggagg tacttggagc ggccgcaata aaatatcttt attttcatta 4850
catctgtgtg ttggtttttt gtgtgaatcg atagtactaa catacgctct 4900
ccatcaaac aaaacgaaac aaaacaaact agcaaaatag gctgtcccca 4950
gtgcaagtgc aggtgccaga acatttctct atcgata 4987



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, C12N 15/63, C07H 21/04 :	A3	(11) International Publication Number: WO 00/34435 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/28451 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 09/206,887 8 December 1998 (08.12.98) US (71) Applicant: CLONTECH LABORATORIES, INC. [US/US]; 1020 East Meadow Drive, Palo Alto, CA 94303 (US). (72) Inventors: LI, Xianqiang; 3989 Aiddlefield Road, Palo Alto, CA 94303 (US). ZHAO, Xiaoning; 110 E. Remington Drive #20, Sunnyvale, CA 94087 (US). JIANG, Xin; 1133 Rejcovich Way, San Jose, CA 95120 (US). FANG, Yu; 43059 Starr Street, Fremont, CA 94539 (US). DUONG, Tommy; 2491 Glen Elm Way, San Jose, CA 95148 (US). KAIN, Steve; 403 Read Avenue, Belmont, CA 94002 (US). (74) Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).		(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 12 October 2000 (12.10.00)
(54) Title: <i>CIS</i> -ELEMENT REPORTER CONSTRUCTS AND USES THEREOF (57) Abstract The present invention provides <i>cis</i> element-reporter constructs for measuring transcription. A series of <i>cis</i> elements are linked to a reporter gene to generate <i>cis</i> -acting reporters. Examples of reporter genes are secreted alkaline phosphatase (SEAP), destabilized green fluorescent protein (d2EGFP) and luciferase. Also provided are various applications of such constructs.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/28451

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12N 15/63; C07H 21/04

US CL : 435/6, 320.1, 455; 536/23.1, 24.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 320.1, 455; 536/23.1, 24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST; DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	US 5,721,340A (HALAZONETIS) 24 February 1998, see especially columns 22,23,29, 30 and the Figures.	1-4, 8-10 ----- 1-11
Y, P	US 5,861,249A (BEACH et al.) 19 January 1999, see especially columns 22, 23, 29 and the Figures.	1-11
Y, P	US 5,877,207A (KLEIN et al.) 02 March 1999, see especially column 133.	1-11
Y	SEGAWA et al. Abrogation of p53-mediated transactivation by SV40 large T antigen. Oncogene 1993, Vol. 8, No. 3, pages 543-548, see especially the abstract, introduction and materials and methods.	1-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

26 MAY 2000

Date of mailing of the international search report

13 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM SANDALS

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/28451

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	UBERALL et al. Role of protein kinase C in Ras-mediated Fos-expression. Advan. Ezyme Regul., 1994, Vol. 34, pages 257-268, see especially the abstract, introduction and materials and methods.	1-11
Y	HUANG et al. Functional recognition of the neuronal tyrosine hydroxylase cAMP regulatory element in different cell types, Molecular Brain Res. Vol. 11, 1991, pages 309-319, see especially the abstract and introduction	1-11
Y	FERNANDEZ-VASQUEZ et al. Transcriptional activation of the gonadotropin-releasing hormone receptor gene by activin A, Endocrinology, 1996, Vol. 10, pages 356-366, see especially the abstract, introduction and materials and methods.	1-11
Y	SICA et al. Interaction of NF-kB and NFAT with the interferon-gamma promoter, J. Biol. Chem., 28 November 1997, pages 30412-30420, see especially the abstract, introduction and materials and methods.	1-11
Y	GHOSH et al. Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway, J. Biol. Chem., 29 March 1996, Vol. 271, number 13, pages 7700-7704, see especially pages the abstract, introduction and materials and methods.	1-11
X ---	OHMORI et al. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer activator of transcription 1 and nuclear factor kB, J. Biol. Chem., 1997, Vol. 272, number 23, pages 14899-14907, see especially the abstract, introduction, materials and methods and the Figures.	1-4 and 8-9
Y		----
X ---	GOTO et al. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kB, Molecular Pharmacology, 1996, Vol. 49, pages 860-873, see especially the abstract, introduction, page 862, column 2, bottom bridging to page 863 column 1, bottom and the Figures.	1-11
Y		----
Y	CHEN et al. The kB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth, J. Virol. July 1997, Vol. 71, No. 7, pages 5495-5504, see especially the abstract and introduction.	1-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/28451

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LI et al. Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones, Biochem. Biophys. Res. Comm., 1996, Vol. 219, pages 96-99, see especially the abstract, introduction and materials and methods.	1-11
Y	MITSUDA et al. Transcriptional regulation of the mouse presenilin-1 gene, J. Biol. Chem., September. 1997, pages 23489-23497, see especially the abstract, introduction and materials and methods.	1-11

BLANK PAGE

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

BLANK PAGE